Zoetis management check
ZTS · Health Care · Pharmaceuticals · CEO Kristin C. Peck
Filings as of
6 good · 0 to watch · 1 flagged, across the seven questions below.
- Flag
Have owners done well?
Trailed its chosen peers$100 invested at the start of fiscal 2021 grew to $80, against $188 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.87 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good
What does the CEO cost owners?
0.7% of net income$19.0m of reported pay in fiscal 2025, against $2.7bn of net income.
- Good
Do they own the stock?
Insiders are buying3 insiders bought $886k on the open market in the last six months, with their own money, near the lows.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -2.0% a year over the last three fiscal years. Stock-based pay was 0.9% of revenue in the latest year.
- Good
Is leadership stable?
9 leadership filings in 3 yearsCEO in the pay table: Kristin C. Peck. 9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 0 | 26 | |
| Pay for performance | 93 | 85 | |
| CEO cost | 62 | 44 | |
| Skin in the game | 80 | 46 | |
| Dilution | 75 | 68 | |
| Stable leadership | 80 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Pharmaceuticals, by management score. Zoetis is 18th of 60 in its sector.
- 32LLYLilly (Eli)84
- 181ZTSZoetis70
- 190JNJJohnson & Johnson69
- 207BMYBristol Myers Squibb68
- 263PFEPfizer64
- 323MRKMerck & Co.60
- 369VTRSViatris57
Pay versus performance
From the proxy statement filed April 8, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Kristin C. Peck | $19.0m | $2.8m | $4.0m | $80 | $188 | $2.7bn |
| 2024 | — | $17.2m | $760k | $3.4m | $102 | $148 | $2.5bn |
| 2023 | — | $15.2m | $26.4m | $3.0m | $122 | $137 | $2.3bn |
| 2022 | — | $14.0m | −$15.7m | $2.9m | $90 | $136 | $2.1bn |
| 2021 | — | $13.1m | $33.5m | $4.5m | $148 | $126 | $2.0bn |
The board says pay is tied most to Revenue. Its other key measures: Relative Total Shareholder Return, Adjusted Diluted EPS, Free Cash Flow.
Insiders and the CEO's stake
3 insiders bought $886k on the open market in the last six months, with their own money, near the lows.
- BoughtFrank A DamelioDirector$501kMay 13, 2026
- BoughtMichael B MccallisterDirector$233kMay 11, 2026
- BoughtPaul BisaroDirector$152kMay 13, 2026
Leadership and governance on file
- Oct 13, 2026Leadership change8-K 5.02
- Aug 6, 2026Leadership change8-K 5.02
- May 22, 2026Leadership change8-K 5.02
- Oct 28, 2025Leadership change8-K 5.02
- May 22, 2025Leadership change8-K 5.02
- May 24, 2024Leadership change8-K 5.02
- May 23, 2024Leadership change8-K 5.02
- Apr 16, 2024Leadership change8-K 5.02
- Apr 1, 2024Leadership change8-K 5.02
- Feb 7, 2023Leadership change8-K 5.02
- Oct 25, 2022Leadership change8-K 5.02
- Jul 25, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 22, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $8.5bn returned to owners in buybacks and dividends, 73% of net income, and $337.0m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $7.8bn | $8.1bn | $8.5bn | $9.3bn | $9.5bn |
| Net income | $2.0bn | $2.1bn | $2.3bn | $2.5bn | $2.7bn |
| Stock-based pay | $58.0m | $62.0m | $60.0m | $74.0m | $83.0m |
| Buybacks | $743.0m | $1.6bn | $1.1bn | $1.9bn | $3.2bn |
| Dividends | — | — | — | — | — |
| Diluted shares | 477m | 470m | 462m | 455m | 444m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.